Breast Cancer Resistant Phenotypes Dream Team - Stand Up To Cancer

Dream Teams

Research  >  Research Portfolio  >  Dream Teams  >  Breast Cancer Resistant Phenotypes Dream Team

SU2C Breast Cancer Dream Team:
An Integrated Approach to Targeting Breast Cancer Molecular Subtypes and Their Resistance Phenotypes

Grant Term: October 2009−September 2014

The SU2C Breast Cancer Dream Team addresses the most significant issues related to the three major subtypes of breast cancer—ER positive, HER2 positive, and triple negative. It uses its findings to develop innovative and less toxic therapies with the potential to improve the treatment outcomes for women with this disease.

ABOUT THIS TEAM’S RESEARCH

During the past several years, researchers have come to understand that breast cancer is not a single disease but rather a spectrum of conditions that vary in their biology and response to treatment. The SU2C Breast Cancer Dream Team focuses on three major subtypes of breast cancer—ER positive, HER2 positive, and triple negative (that is, simultaneously ER negative, PR negative, and HER2 negative)—with the hope of developing novel therapies for women with this disease.

Over time, cancer cells can develop ways of “outsmarting” the drugs and agents designed to kill them, a phenomenon known as drug resistance. This Dream Team studies the driving mechanisms that lead to drug resistance and the role that cancer stem cells play in resistance.

The team has gathered the vast amount of information that exists about breast cancer into an integrated database to form a “discovery platform”—a basis for identifying and validating new drug combinations and targets that can be pursued in clinical trials.

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.